Wyeth Pharmaceuticals, a division of Wyeth , announced today that the Company has received an approvable letter from the U.S. Food and Drug Administration for Pristiq , a serotonin-norepinephrine reuptake inhibitor studied as a treatment for adult patients with major depressive disorder .
From: biz.yahoo.com
Desvenlafaxine Succinate) for the Treatment of Major Depressive ...
Posted by Ruslan Abuzant at 2:48 PM
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment